Deanna L. Kirkpatrick

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 1.750% bonds due 2024, issued by the Province of British Columbia. The…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of $1.25 billion aggregate principal amount of its floating-rate senior notes due 2021, under its medium-term…

Davis Polk advised Silver Spike Acquisition Corp. on its $250 million initial public offering of 25,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A…

Davis Polk advised the underwriters in connection with the offering of C$500 million aggregate principal amount of 1.650% Canadian dollar bonds due 2024 issued by Export Development Canada…

Davis Polk advised representatives of the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.750% U.S. dollar bonds due 2022 issued by Export…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…

Davis Polk advised the underwriters in connection with the offering of $1.75 billion aggregate principal amount of 2.300% bonds due June 15, 2026 issued by the Province of Ontario. The…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…